ATE306257T1 - Pharmazeutische zusammensetzung enthaltend ein alpha-ketoalkansäureester oder -amid und milchsäure oder ein milchsäuresalz - Google Patents

Pharmazeutische zusammensetzung enthaltend ein alpha-ketoalkansäureester oder -amid und milchsäure oder ein milchsäuresalz

Info

Publication number
ATE306257T1
ATE306257T1 AT03726353T AT03726353T ATE306257T1 AT E306257 T1 ATE306257 T1 AT E306257T1 AT 03726353 T AT03726353 T AT 03726353T AT 03726353 T AT03726353 T AT 03726353T AT E306257 T1 ATE306257 T1 AT E306257T1
Authority
AT
Austria
Prior art keywords
lactic acid
alpha
ketoalkanoic
amide
pharmaceutical composition
Prior art date
Application number
AT03726353T
Other languages
German (de)
English (en)
Inventor
Mitchell P Fink
Original Assignee
Critical Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Critical Therapeutics Inc filed Critical Critical Therapeutics Inc
Application granted granted Critical
Publication of ATE306257T1 publication Critical patent/ATE306257T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/223—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of alpha-aminoacids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/225—Polycarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT03726353T 2002-04-17 2003-04-17 Pharmazeutische zusammensetzung enthaltend ein alpha-ketoalkansäureester oder -amid und milchsäure oder ein milchsäuresalz ATE306257T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37368002P 2002-04-17 2002-04-17
PCT/US2003/012134 WO2003088955A1 (en) 2002-04-17 2003-04-17 Pharmaceutical composition comprising an alpha-ketoalkanoic acid ester or -amine and lactic acid or a lactic acid salt

Publications (1)

Publication Number Publication Date
ATE306257T1 true ATE306257T1 (de) 2005-10-15

Family

ID=29251059

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03726353T ATE306257T1 (de) 2002-04-17 2003-04-17 Pharmazeutische zusammensetzung enthaltend ein alpha-ketoalkansäureester oder -amid und milchsäure oder ein milchsäuresalz

Country Status (8)

Country Link
US (2) US20030216470A1 (enExample)
EP (2) EP1494659B1 (enExample)
JP (2) JP2005527592A (enExample)
AT (1) ATE306257T1 (enExample)
AU (2) AU2003230996A1 (enExample)
CA (2) CA2481753A1 (enExample)
DE (1) DE60301878T2 (enExample)
WO (2) WO2003088955A1 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE602004014140D1 (de) * 2003-06-13 2008-07-10 Univ Pittsburgh Verfahren zur behandlung von alkoholischer hepatitis
US7464564B2 (en) * 2003-09-22 2008-12-16 Dippin' Dots, Inc. Method and apparatus for combining cookie dough and ice cream
US20050106301A1 (en) * 2003-09-24 2005-05-19 Curt Jones Method and apparatus for cryogenically manufacturing ice cream
EP1689431A4 (en) * 2003-10-27 2010-11-17 Univ Pennsylvania CYTOPROTECTIVE EFFECTS OF ETHYL PYRUVATE
US7316122B1 (en) 2004-01-06 2008-01-08 Dippin' Dots, Inc. Tray for producing particulate food products
US20060062877A1 (en) * 2004-09-21 2006-03-23 Curt Jones Method and apparatus for storing food products
US20060093714A1 (en) * 2004-11-01 2006-05-04 Dippin' Dots, Inc. Particulate ice cream dot cake
US20060093719A1 (en) * 2004-11-01 2006-05-04 Dippin' Dots, Inc. Particulate ice cream dot sandwich
WO2006108681A2 (en) 2005-04-15 2006-10-19 Biomac Privatinstitut Für Medizinische Und Zahnmedizinische Forschung, Entwicklung Und Diagnostik Gmbh Substances and pharmaceutical compositions for the inhibition of glyoxalases and their use against bacteria
US7332315B2 (en) * 2005-08-17 2008-02-19 Colgate-Palmolive Company Method to remove bisulfite by-products from enzyme compositions
US20070134394A1 (en) * 2005-12-12 2007-06-14 Dippin' Dots, Inc. Method of manufacturing particulate ice cream for storage in conventional freezers
US20070140044A1 (en) * 2005-12-15 2007-06-21 Dippin' Dots, Inc. Combined particulate and traditional ice cream
US20070140043A1 (en) * 2005-12-16 2007-06-21 Stan Jones Method and apparatus of combining food particles and ice cream
WO2007120544A2 (en) 2006-04-12 2007-10-25 Alexander Rayna L Compositions comprising pyruvate alkyl esters and uses thereof
US8603513B2 (en) * 2007-06-28 2013-12-10 The Procter & Gamble Company Article comprising calcium for reducing the production of TSST-1
EP2326317A1 (en) * 2008-09-19 2011-06-01 Cytokine Pharmasciences, Inc Guanylhydrazones for treatment of postoperative intestinal inflammation
CN106727320A (zh) * 2017-01-13 2017-05-31 江苏长泰药业有限公司 一种用于修复鼻粘膜、降低过敏反应、抗炎作用的组合物

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3984556A (en) * 1973-01-19 1976-10-05 Sandoz, Inc. Alkyl-substituted-tricyclic quinazolinones for lowering blood pressure
US3879537A (en) * 1973-09-04 1975-04-22 Scott Eugene J Van Treatment of ichthyosiform dermatoses
US3988470A (en) * 1974-02-25 1976-10-26 Scott Eugene J Van Treatment of palmar and plant disturbed keratosis
US4021572A (en) * 1975-07-23 1977-05-03 Scott Eugene J Van Prophylactic and therapeutic treatment of acne vulgaris utilizing lactamides and quaternary ammonium lactates
US4645764A (en) * 1981-04-01 1987-02-24 Montefiore Hospital Method for preventing body fat deposition in animals
US4812479A (en) * 1981-04-01 1989-03-14 The Montefiore Hospital Society Of Western Pennsylvania, Inc. Method for preventing body fat deposition in mammals
US4351835A (en) * 1981-04-01 1982-09-28 Montefiore Hospital Method for preventing body fat deposition in mammals
US4548937A (en) * 1981-04-01 1985-10-22 Montefiore Hospital Method for preventing body fat deposition in mammals
US4415576A (en) * 1981-04-01 1983-11-15 Montefiore Hospital Method for preventing body fat deposition in mammals
DE3581407D1 (de) * 1985-09-06 1991-02-21 Nestle Sa Bewahrung lebender gewebe.
WO1987003808A1 (en) * 1985-12-18 1987-07-02 Veech Richard L Fluid therapy with l-lactate and/or pyruvate anions
US5389677B1 (en) * 1986-12-23 1997-07-15 Tristrata Inc Method of treating wrinkles using glycalic acid
AU618517B2 (en) * 1986-12-23 1992-01-02 Eugene J. Van Scott Additives enhancing topical actions of therapeutic agents
US5091171B2 (en) * 1986-12-23 1997-07-15 Tristrata Inc Amphoteric compositions and polymeric forms of alpha hydroxyacids and their therapeutic use
US6051609A (en) * 1997-09-09 2000-04-18 Tristrata Technology, Inc. Additives enhancing the effect of therapeutic agents
US4988515A (en) * 1988-01-28 1991-01-29 The Regents Of The Univ. Of Calif. Cardioplegic solution
EP0345082A3 (en) * 1988-06-02 1990-04-04 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Enzyme formation suppressing agent
US5147650A (en) * 1988-07-29 1992-09-15 University Of Florida Compositions and methods for achieving improved physiological response to exercise
US4981687A (en) * 1988-07-29 1991-01-01 University Of Florida Compositions and methods for achieving improved physiological response to exercise
US4874790A (en) * 1988-08-15 1989-10-17 Montefiore Hospital Association Of Western Pennsylvania Method for improving the glucose metabolism of an animal having diabetic tendencies
US5066578A (en) * 1989-12-21 1991-11-19 The Regents Of The University Of California Long-term preservation of organs for transplantation
US5075210A (en) * 1989-12-21 1991-12-24 The Regents Of The University Of California Preservation of the heart for transplantation
US5210098A (en) * 1990-09-21 1993-05-11 Regents Of The University Of Minnesota Use of pyruvate to treat acute renal failure
US5134162A (en) * 1990-12-24 1992-07-28 The Montefiore Hospital Association Of Western Pennsylvania Method for lowering high blood cholesterol levels in hyperlipidemic animals and confections as the ingestion medium
US5981606A (en) * 1991-03-01 1999-11-09 Warner-Lambert Company Therapeutic TGF-beta-wound healing compositions and methods for preparing and using same
US5874479A (en) * 1991-03-01 1999-02-23 Warner-Lambert Company Therapeutic permeation enhanced-wound healing compositions and methods for preparing and using same
US5658956A (en) * 1991-03-01 1997-08-19 Warner-Lambert Company Bioadhesive-wound healing compositions and methods for preparing and using same
US5648380A (en) * 1991-03-01 1997-07-15 Warner-Lambert Company Anti-inflammatory wound healing compositions and methods for preparing and using same
US5658957A (en) * 1991-03-01 1997-08-19 Warner Lambert Company Immunostimulating wound healing compositions and method for preparing and using same
US5674912A (en) * 1991-03-01 1997-10-07 Warner-Lambert Company Sunscreen-wound healing compositions and methods for preparing and using same
US5652274A (en) * 1991-03-01 1997-07-29 Martin; Alain Therapeutic-wound healing compositions and methods for preparing and using same
US5633285A (en) * 1991-03-01 1997-05-27 Warner-Lambert Company Cytoprotective wound healing compositions and methods for preparing and using same
US5863938A (en) * 1991-03-01 1999-01-26 Warner Lambert Company Antibacterial-wound healing compositions and methods for preparing and using same
US5294641A (en) * 1991-11-27 1994-03-15 Montefiore - University Hospital Method for treating a medical patient for cardiac trauma
US5256697A (en) * 1992-04-16 1993-10-26 Abbott Laboratories Method of administering pyruvate and methods of synthesizing pyruvate precursors
US5508308A (en) * 1992-04-16 1996-04-16 Abbott Laboratories Use of pyruvylglycine to treat ischemia/reperfusion injury following myocardial infarction
PT701455E (pt) * 1993-06-04 2001-09-27 Biotime Inc Solucao semelhante a plasma
US5395822A (en) * 1993-09-20 1995-03-07 Izumi; Yukitoshi Use of pyruvate to prevent neuronal degeneration associated with ischemia
US5612374A (en) * 1994-02-14 1997-03-18 Ronald T. Stanko Inhibiting growth of mammary adenocarcinoma
US5536751A (en) * 1994-05-09 1996-07-16 The United States Of America As Represented By The Secretary Of The Army Pharmaceutical alpha-keto carboxylic acid compositions method of making and use thereof
US5480909A (en) * 1994-08-08 1996-01-02 University Of Pittsburgh Medical Center Method for inhibiting generation of free-radicals
US5801198A (en) * 1995-07-13 1998-09-01 University Of Pittsburgh Medical Center Retarding neutrophil infiltration ad morphologic reduction in ischemic bowel tissues
US5798388A (en) * 1996-09-06 1998-08-25 Cellular Sciences, Inc. Method and composition for treating mammalian diseases caused by inflammatory response
US5876916A (en) * 1996-03-18 1999-03-02 Case Western Reserve University Pyruvate compounds and methods for use thereof
US6086789A (en) * 1996-03-18 2000-07-11 Case Western Reserve University Medical uses of pyruvates
US5667962A (en) * 1996-03-18 1997-09-16 Case Western Reserve University Pyruvate thiolester for the prevention of reperfusion injury
US5843024A (en) * 1996-05-17 1998-12-01 Breonics, Inc. Solution and process for resuscitation and preparation of ischemically damaged tissue
US5756469A (en) * 1996-07-26 1998-05-26 Beale; Paxton K. Composition of pyruvate and anti-cortisol compounds and method for increasing protein concentration in a mammal
US6417231B1 (en) * 1996-12-23 2002-07-09 Frank L. Greenway Method and composition for delivering therapeutically effective amounts of pyruvate to a mammal
GB9724813D0 (en) * 1997-11-25 1998-01-21 Univ Nottingham Reducing muscle fatigue
CN1377266A (zh) * 1999-10-07 2002-10-30 安瑟斯生命科学公司 丙酮酸酯组合物和其在缺血和灌流后复苏中的应用方法

Also Published As

Publication number Publication date
DE60301878T2 (de) 2006-08-10
EP1494659B1 (en) 2005-10-12
CA2481749A1 (en) 2003-10-30
US20030232884A1 (en) 2003-12-18
CA2481753A1 (en) 2003-10-30
JP2005527592A (ja) 2005-09-15
AU2003230996A1 (en) 2003-11-03
WO2003088956A1 (en) 2003-10-30
AU2003228593B2 (en) 2006-07-27
AU2003228593A1 (en) 2003-11-03
WO2003088955A1 (en) 2003-10-30
EP1494659A1 (en) 2005-01-12
EP1496883A1 (en) 2005-01-19
DE60301878D1 (de) 2006-02-23
WO2003088956A8 (en) 2004-04-15
JP2005526832A (ja) 2005-09-08
US20030216470A1 (en) 2003-11-20

Similar Documents

Publication Publication Date Title
ATE306257T1 (de) Pharmazeutische zusammensetzung enthaltend ein alpha-ketoalkansäureester oder -amid und milchsäure oder ein milchsäuresalz
ATE419039T1 (de) Pharmazeutische kombinationen von oxycodon und naloxon
ATE464049T1 (de) Pharmazeutische kombinationen von hydrocodon und naltrexon
NO2014005I1 (no) olodaterol, syreaddisjonssalter og farmakologisk akseptable syrer derav
BR0009043A (pt) Composto, composição farmacêutica, e, método de tratar uma doença em um animal em que a atividade da cisteìna protease contribui para a patologia e/ou sintomatologia da doença
DE60003837D1 (de) Tetrapeptid, das die funktionelle aktivität von neuronen stimuliert, dieses enthaltendes pharmakologisches mittel und seine verwendung
GEP20074208B (en) Substituted amides active at the cannabinoid-1 receptor
EP2615087A3 (en) Phenylalanine derivatives
NO20065904L (no) Terapeutiske forbindelser
DE602005009974D1 (de) Eichung von biologischen oder pharmazeutischen substanzen
ATE402175T1 (de) 4-oxo-1-(3-substituiertesphenyl)-1,4-dihydro-1, - naphthyridin-3-carbonsäureamide alsphoshodiesterase-4-inhibitoren
MA28862B1 (fr) Composition pharmaceutique sous forme de comprime a residence gastrique contenant un principe actif
HUP0302441A2 (hu) Antibiotikus hatású gyógyászati készítmények
NO20073457L (no) Stabile sammensetninger av fenofibrat med fettsyreestere
EP1604659A4 (en) TABLET WITH WATER TAKING AMINO ACID
EA200401303A1 (ru) Лекарственные средства, содержащие стероиды и новое антихолинергическое средство
MXPA05008403A (es) Uso de acido comestible en formas de dosis solidas farmaceuticas de rapida dispersion.
TW200500070A (en) Method of improved diuresis in individuals with impaired renal function
EP1784173A4 (en) PHARMACEUTICAL COMPOSITION FOR THE PREVENTION AND TREATMENT OF METABOLIC BONE DISEASES WITH ALPHA-ARYLMETHOXYACRYLATE DERIVATIVES
BR0312712A (pt) Aminoácido modificado para a inibição da agregação plaquetária
RU2005135647A (ru) Комбинации, включающие пароксетин и {1-(r)-(3.5-бис-трифтор-2-метилфенил) этилметиламид}-2-(s)-(4-фтор-2-метилфенил) пиперазин-1-карбоновой кислоты, для лечения депрессии и/или тревоги
ATE428709T1 (de) Anthranilsäureamide und ihre pharmazeutische verwendung
HRPK20040328B3 (en) Pharmaceutical composition comprising gamma-butyrobetaine
ECSP045210A (es) 2' - halo - 3' , 5' - dialcoxi - fen - 1' - il - imino - 2 -imidazolidinas y su uso como un fármaco
ATE331509T1 (de) Zusammensetzung die paracetamol und niflumic säure enthält

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties